Most Read Articles
Pearl Toh, 30 Apr 2019
A shorter regimen comprising a seven-drug cocktail which included high-dose moxifloxacin for 9 months was noninferior to the WHO*-recommended long regimen of 20 months for treating rifampicin-resistant tuberculosis (TB), according to the STREAM** study, providing a feasible and lower-cost treatment option in resource-poor setting.
31 Jan 2017
New drug applications approved by US FDA as of 16 - 31 January 2017 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Advancing the treatment paradigm of idiopathic pulmonary fibrosis (IPF)

22 Jan 2018
Literature suggests that IPF is either the first or second most common interstitial lung disease (ILD) in pulmonology practice, with prevalence ranging from 17–86%. At the recent 3rd Respiratory Forum organized by Boehringer Ingelheim, Dr Felix Chua shared his insights into the importance of advancing the treatment paradigm of IPF, and the role of nintedanib (OFEV®) in its management.

Related MIMS Drugs

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Respirology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 30 Apr 2019
A shorter regimen comprising a seven-drug cocktail which included high-dose moxifloxacin for 9 months was noninferior to the WHO*-recommended long regimen of 20 months for treating rifampicin-resistant tuberculosis (TB), according to the STREAM** study, providing a feasible and lower-cost treatment option in resource-poor setting.
31 Jan 2017
New drug applications approved by US FDA as of 16 - 31 January 2017 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.